NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis $5.25 +0.35 (+7.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.91▼$5.2750-Day Range$3.19▼$5.2552-Week Range$1.94▼$8.31Volume229,875 shsAverage Volume240,385 shsMarket Capitalization$296.60 millionP/E RatioN/ADividend YieldN/APrice Target$6.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Design Therapeutics alerts: Email Address Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside25.7% Upside$6.60 Price TargetShort InterestBearish9.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.19Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.02) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 starsMedical Sector744th out of 936 stocksPharmaceutical Preparations Industry347th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Design Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.20% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Design Therapeutics has recently increased by 3.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 4.0 News and Social Media Coverage News SentimentDesign Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Design Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for DSGN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Design Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Design Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesJuly 26 at 1:12 AM | americanbankingnews.comAnalysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Price Target at $6.60May 25, 2024 | finanznachrichten.deDesign Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 22, 2024 | investorplace.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 20, 2024 | msn.comLarimar stock rallies 24% on FDA removal of partial clinical holdMay 10, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewMay 10, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial ReviewMay 9, 2024 | msn.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 8, 2024 | globenewswire.comDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 7, 2024 | msn.comPiper Sandler Upgrades Design Therapeutics (DSGN)May 7, 2024 | msn.comDesign Therapeutics climbs as Piper Sandler upgrades on pipelineMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Design Therapeutics’ Innovative Pipeline and Solid FinancialsMay 7, 2024 | globenewswire.comDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMarch 27, 2024 | finance.yahoo.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 26, 2024 | msn.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 21, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)March 21, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program UpdatesSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+25.7%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.79% Return on Assets-19.89% Debt Debt-to-Equity RatioN/A Current Ratio38.61 Quick Ratio38.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.96 per share Price / Book1.06Miscellaneous Outstanding Shares56,495,000Free Float38,869,000Market Cap$296.60 million OptionableOptionable Beta1.82 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 54)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $704.1kDr. Sean Jeffries Ph.D. (Age 44)Chief Operating Officer Comp: $554.01kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Jae B. Kim FACC (Age 54)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsAtai Life SciencesNASDAQ:ATAISyros PharmaceuticalsNASDAQ:SYRSSangamo TherapeuticsNASDAQ:SGMOBurning Rock BiotechNASDAQ:BNRPrecision BioSciencesNASDAQ:DTILView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 2,868 shares on 7/26/2024Ownership: 0.209%Opaleye Management Inc.Bought 113,038 shares on 5/29/2024Ownership: 0.200%Jacobs Levy Equity Management Inc.Sold 47,098 shares on 5/16/2024Ownership: 0.889%Public Employees Retirement System of OhioSold 2,590 shares on 5/15/2024Ownership: 0.042%Price T Rowe Associates Inc. MDBought 11,147 shares on 5/15/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions How have DSGN shares performed this year? Design Therapeutics' stock was trading at $2.65 on January 1st, 2024. Since then, DSGN stock has increased by 98.1% and is now trading at $5.25. View the best growth stocks for 2024 here. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) posted its earnings results on Wednesday, May, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Top institutional investors of Design Therapeutics include Bank of New York Mellon Corp (0.21%). Insiders that own company stock include Sr One Capital Fund I Aggregat, Simeon George, Rodney W Lappe, Joao Md Siffert, John P Schmid, Deepa Prasad, Stella Xu and Arsani William. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
